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Summary
AIMS OF THE STUDY: To assess the cost-effectiveness of
primarily surgical treatment (PST) versus primarily conser-
vative treatment (PCT) in adults with intermediate sever-
ity, acute or subacute, lumbar radicular syndrome due to in-
tervertebral disc herniation.
METHODS: A decision analytic model from healthcare
system and societal perspectives was used to compare out-
comes and costs of PST with those of PCT (physiotherapy,
epidural injection and medication). Treatment pathways
and quality of life were obtained from published clinical
trials. Costs were derived from Swiss health insurance
claims data. Swiss clinical experts provided information on
use of medication and physiotherapy. The main outcome of
interest was incremental cost per quality-adjusted-life-year
(QALY) gained over a period of 2 years. Costs and QALYs
gained were discounted from the second year, at a rate of
2% per year.
RESULTS: In the base-case analysis from a healthcare sys-
tem perspective, over 2 years, PST compared with PCT led
to 0.0634 additional QALYs per person, at an additional
net cost of CHF 7198 per person. The corresponding incre-
mental cost effectiveness ratio (ICER) amounted to CHF
113 396 per QALY gained. From a societal perspective the
ICER was CHF 70 711 per QALY gained. ICERs were
subject to substantial uncertainty because of limitations in
available data.
CONCLUSION: A PST approach, when compared with
PCT, may be cost effective from a societal perspective
based on a willingness-to-pay threshold of CHF 100 000
per QALY gained. However, it is less likely to be cost ef-
fective from the perspective of the Swiss healthcare sys-
tem. More research is needed to understand the long-term
economic implications among this patient group.
Key words: lumbar spine; acute or subacute lumbar
radiculopathy; intervertebral disc herniation; economics;
cost-effectiveness
Introduction
Intervertebral disc herniation usually occurs after second-
ary degenerative changes and is characterised by the pro-
trusion or prolapse of disc material, which in turn can lead
to the compression of spinal nerves (radiculopathy) [1].
The choice of treatment, conservative or surgical, depends
on symptom severity. In some instances, the recommenda-
tion for immediate surgery is made because of severe neur-
ological symptoms, such as cauda equina syndrome. In
other cases, the choice may be less clear. Typically, these
patients do not fully recover despite conservative treatment
and the choice then needs to be made between continuing
with the conservative treatment or opting for a surgical in-
tervention.
According to the Agency for Health Research and Quality
in the US, the majority of disc herniation surgeries are per-
formed on patients in the working age group, and have an
important impact on quality of life and productivity [2]. In
2012, lumbar and other intervertebral disc disorders with
radiculopathy due to a herniated disc were the sixth most
common diagnosis (9892 cases) among inpatient episodes
in Swiss acute care hospitals [3].
Several cost-effectiveness analyses have compared surgery
with conservative treatment [4–8], and reported favourable
results for surgery. However, methodological approaches
were dissimilar and the available evidence cannot be as-
sumed to hold for Switzerland owing to differences in the
utilisation of healthcare resources and clinical practice. In
the present analysis, we use the terms “primarily surgical
treatment approach” (PST; for example, microdiscectomy
[9], unilateral transflaval approach using magnification, or
bilateral exploration [10]) and “primarily conservative
treatment approach” (PCT; broadly defined as involving,
for example, physiotherapy, epidural injection or medica-
tion). In patients receiving PCT, subsequent crossover to
surgical treatment remains a possibility, whereas some pa-
tients planned for PST may finally not undergo operation.
We aimed to estimate the cost-effectiveness of PST versus
PCT, among adults with intermediate severity, acute
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(symptoms for less than 6 weeks) or subacute (symptoms
for 6–12 weeks) lumbar radicular syndrome due to in-
tervertebral disc herniation, from both Swiss healthcare
system and societal perspectives. It was assumed that pa-
tients already had initial, conservative treatment before the
decision on PST versus PCT.
Methods
Overview of the approach and model
A decision analytic model was developed to represent the
management pathway for adults with acute or subacute
lumbar radicular syndrome due to intervertebral disc her-
niation. The model was configured as a decision tree [11]
comparing PST and PCT. The model is depicted in figure 1.
The branches representing PST and PCT were divided into
subbranches. PCT patients could either “continue with con-
servative treatment”, or “not respond to conservative treat-
ment AND undergo surgery”. Similarly, PST patients could
either “undergo surgery” or undergo “no surgery AND con-
tinue with conservative treatment”. Clinical data indicating
the impact of the initial treatment approach was limited to
2 years and therefore a 2-year time horizon was chosen for
the base-case analysis [6, 12].
In the base-case analysis, the costs and the quality-adjusted
life years (QALYs) gained were discounted after the first
year with a rate of 2.0% per year [13]. The selected dis-
count rate corresponds to the specification of the Swiss
Medical Board.
Main outcomes were costs per treatment, QALYs per treat-
ment, and incremental cost-effectiveness expressed as the
cost per QALY gained, from both healthcare system and
the societal perspectives.
The base-case model was structured such that individuals
assigned to PST who did not undergo surgery would oth-
erwise be managed as individuals who “undergo surgery”.
Hence, their downstream effects and costs were the same
as those of individuals who did undergo surgery, with the
exception of surgery costs. The reason for this assumption
was that the underlying clinical trials reported average res-
ults per study arm and did not differentiate between the
clinical outcomes of per-protocol and crossover patients.
A similar assumption was made for individuals assigned
to PCT who crossed over to surgery: namely that they
would have similar downstream effects, medical examina-
tions and related costs as individuals who remained on con-
servative treatment, with the exception of additional sur-
gery costs (fig. 1). In sensitivity analyses, the probability of
Figure 1
Decision analysis tree comparing primarily conservative treatment
(PCT) with primarily surgical treatment (PST) approach.
individuals assigned to PCT who crossed over to surgical
treatment was varied to reflect populations with alternative
risk profiles.
Patient population
Our population of interest comprised patients with acute
(symptoms for less than 6 weeks) or subacute (symptoms
for 6–12 weeks) lumbar radiculopathy due to disc herni-
ation at the lumbar spine. Lumbar radiculopathy had to
be confirmed clinically and disc herniation had to be con-
firmed by imaging (computed tomography, magnetic res-
onance imaging or myelography). In the clinical trials
available, patients had typically undergone PCT before
they were enrolled. Patients with severe neurological defi-
cits (such as cauda equina syndrome), radiculopathy with
neoplasia or epidural abscess, as well as patients with very
minor symptoms, were not part of the population of in-
terest.
The path probabilities of the decision analytic model were
based on the randomised controlled trials (RCTs) of Peul
et al., Österman et al. and Weber et al. [1, 14, 15]. The in-
cluded studies were conducted in Finland (Österman et al.
[15]), the Netherlands (Peul et al. [14]) and Norway (We-
ber et al. [1]). The number of randomised patients in the
smallest study, by Österman et al. [15], was 56, and the lar-
ger studies of Weber and Peul et al. [1, 14] had 126 and
283 patients, respectively. The proportion of women var-
ied between 32% and 47%, and the average age at baseline
between 37 and 43 years. The maximum observation peri-
od ranged from 2 to 10 years. The population of interest
had subacute symptoms in the studies of Österman and
Peul et al. [14, 15] and acute symptoms in the study of
Weber et al. [1]. The presence of a hernia was confirmed
by computed tomography in Österman et al. [15], magnet-
ic resonance imaging in Peul et al. [14] and myelography
in Weber et al. [1]. To estimate the probability of crossover
from PCT to PST, a random effects meta-analysis of these
three studies was undertaken (appendix 1), in which 37.0%
of patients managed with PCT moved to surgery. The prob-
ability of patients assigned to PST but not undergoing sur-
gery was also extracted from the three trials, and was 2.0%.
Moreover, the number of reoperations for both treatment
strategies was extracted for 12 and 24 months. Patients in
the PST groups had a 6.0% probability of reoperation, and
patients in the PCT groups who moved to surgery also had
a 6.0% probability of reoperation over 2 years of follow-
up. Details are available in appendices 1 and 2.
Utility associated with PST and PCT
Utilities (quality of life weights) were taken from the cost-
effectiveness analysis of van den Hout et al. [5]. This study
was based on the trial by Peul et al., and was designed to
assess the impact of early surgery versus prolonged con-
servative treatment on Dutch patients with sciatica from
lumbar disc herniation [14]. The instrument used to gen-
erate utilities in van den Hout et al. [5] was the EQ-5D
questionnaire. Utilities were provided only for the first
12 months, with four point estimates over 12 months of
follow-up (appendix 2). In the base-case analysis, we as-
sumed that the difference at 12 months (0.02 on a scale of
0 to 1) was maintained for a further time period up to 24
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months. This assumption was supported by the findings of
Österman et al. [15], in which the utility value difference
at the end of 24 months was 0.02, and of Hansson et al.
[12], where 2-year results were reported. However, for oth-
er reasons described in the discussion, Hansson et al. was
not included in the analyses.
The study by Österman et al. [15] was not considered in the
base-case analysis because of a different method of meas-
uring utilities (use of the 15D instrument), and small stand-
ard deviation of the reported utility estimates, which in-
dicated a possible “ceiling” effect. However, pooled utility
values by Österman et al. [15] and van den Hout et al.
[5], based on random effects meta-analyses (appendix 4),
were applied in a scenario analysis. Also, additional scen-
ario analyses were performed, in which no difference in
utility scores between PST and PCT was assumed for the
second year of the analysis.
Medical resource use and costs data
Costs were estimated both from the Swiss healthcare sys-
tem perspective and from the societal perspective, taking
into account various statistical data for Switzerland for
2011 and 2012, which was the latest available year. These
costs were then updated to 2015 values with use of the
Swiss consumer price index. The consumer price index val-
ues for 2011 to 2015 were 100.2, 99.5, 99.3, 99.3 and 98.2,
respectively [16].
The costs (inpatient, outpatient and pharmaceuticals) for
the base-case analysis were mainly derived from Swiss
health insurance claim data provided by Helsana (a health
insurance provider). These data represent a 14.0% market
share, with higher values in the German-speaking cantons
of Switzerland and lower values in the French-speaking
cantons.
Using the claims data, patients who underwent surgery
due to intervertebral disc herniation were identified by the
Swiss diagnoses related group (SwissDRG) codes I53Z and
I56Z [17] (for definitions, see appendix 3). The base-case
unit costs for hospitalisations are reported in appendix 3.
For scenario analyses, inpatient costs were derived from
two alternative sources, namely costs per SwissDRG as
provided by the Swiss Federal Statistical Office (FSO) and
average inpatient costs per day using Swiss statistical hos-
pital data [18] (appendix 3).
Based on published literature (van den Hout et al. [5] and
Tosteson et al. [6]) and expert opinion, the medical spe-
cialities and services relevant for the outpatient care of
our patient population were identified. These services were
general medicine, physiotherapy, chiropractic, ergotherapy,
neurosurgery, neurology, rheumatology, attendance at a
rheumatology or rehabilitation hospital and therapeutic
baths.
Differences in medical resource use between the PST and
PCT approaches are reported in appendix 2, with their rel-
evant literature sources. Published literature was used to es-
timate the difference in medical resource use between PST
and PCT where available. Where information was lacking,
this was supplemented with assumptions based on clinical
expert opinion. This was required only in the case of drug
use, where estimates provided by four experts were aver-
aged. The Fachgesellschafte (professional societies) pro-
posed clinical experts who received letters of invitation.
Details of research questions and important outcomes were
defined with the clinical experts. Four reports with closed
questions were returned by the clinical experts, describing
information about PST and PCT and their differences with
regards to drug use, physiotherapy sessions, epidural injec-
tions and diagnostic tests.
Medical resource use estimates were then combined with
unit costs extracted from the Helsana dataset to derive out-
patient costs incurred during 12 months and between 12 to
24 months of follow-up (appendix 3).
Unit costs of drugs with relevant Anatomical Therapeutic
Chemical Classification System (ATC) [19] codes in the
Helsana data set were combined with clinical expert es-
timates of the probability of drug use when comparing the
two treatment approaches (appendix 3). Drugs from the
following ATC groups were assumed to be used by our
study population: oral steroids (H02), musculoskeletal sys-
tem including anti-inflammatory and partially antirheum-
atic products, topical products for joint and muscular pain
and muscle relaxants (M01, M02, M03), and products from
the nervous system including anaesthetics, analgesics, psy-
choleptics and psychoanaleptics (N01, N02, N05, N06).
Productivity costs applied in the economic model were
based on the human capital approach, which values lost
work-time using salary levels [20]. Only van den Hout et
al. [5, 14] reported on productivity lost in both treatment
approaches of interest. According to these authors, patients
in “early surgery” lost 377 hours over a 12-month period
of follow-up whereas patients in “prolonged conservative
care” lost 416 hours (difference 39 hours; 95% confidence
interval [CI] −67 to 144 hours). This information was com-
bined with the median Swiss salary level. The median pay
rate per hour was CHF 35.37 (2012 data) [21], which was
then updated to 2015 data, by use of wages and income
from employment indicators (CHF 36.11) [22]. This resul-
ted in mean costs of lost productivity for PST and PCT of
CHF 13 614 and CHF 15 002, respectively. The resulting
difference in indirect costs between PST and PCT in the
first year was CHF 1408, favouring PST. For the second
year we assumed that the difference between the two
strategies would be the same as in the first year. In a scen-
ario analysis, we assumed no difference for the second
year.
Sensitivity analysis
Sensitivity analyses were performed to assess the impact
of uncertainty around model input parameters, especially
those likely to have a relevant effect on the main outcomes,
namely hospital, physiotherapy, medications, general prac-
tice, neurosurgery, crossover, reoperation and productivity
costs. All parameters underlying uncertainty were determ-
inistically varied one at a time, based on their 95% CIs,
where available, or by ±30%. In addition, probabilistic
sensitivity analysis (PSA) was undertaken by assigning
probability distributions to input parameters, reflecting the
ranges of variation used in deterministic sensitivity analys-
is, and performing Monte Carlo simulation with 10 000 it-
erations. All parameters used and their respective distribu-
tions are presented in appendices 2 and 3.
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Additional scenario analyses were necessary owing to un-
certainty that went beyond stochastic uncertainty around
model parameters. The analyses that were undertaken are
presented with the results (see table 3 below).
Microsoft Excel (Microsoft Office Professional Plus 2013,
Redmond, WA, USA), in combination with @Risk (version
6, 2013, [place and country, as above]), was used as the
technical platform for the current model.
Results
Base-case results are summarised in table 1. The PST ap-
proach was characterised by higher surgery costs, but lower
physiotherapy and treatment costs. From a healthcare sys-
tem perspective, the PST approach leads to 0.0634 addi-
tional QALYs (discounted) per person over 2 years, at a
net cost (discounted) of CHF 7198 per person, compared
with the PCT approach. These numbers equate to an ICER
of CHF 113 396 per QALY gained (table 1). From a so-
cietal perspective, which includes all healthcare care costs
Figure 2
Scatter plot of incremental costs per person and incremental
effectiveness derived from 10 000 iterations of the Monte Carlo
simulation. Incremental effectiveness is expressed as quality
adjusted life years (QALYs) gained and incremental costs are in
CHF, from the healthcare system perspective.
Figure 3
Scatter plot of incremental costs per person and incremental
effectiveness derived from 10 000 iterations of the Monte Carlo
simulation. Incremental effectiveness is expressed as quality
adjusted life years (QALYs) gained and incremental costs are in
CHF, from the societal perspective.
and costs of lost productivity, the net costs were CHF 4489
(discounted), implying an ICER of CHF 70 711 per QALY
gained. In the latter case, the estimated difference in total
costs between strategies was reduced because of reductions
in the costs of lost productivity, and therefore the ICER was
improved (table 1).
In the deterministic sensitivity analysis, results were mostly
sensitive to the costs of surgery, utility values and pro-
ductivity costs (table 2). For example, the use of upper lim-
its for utility values increased the ICER, favouring PCT. In
contrast, the use of upper limits for values of productivity
costs made PST a cost saving (dominant) approach.
Scenario analysis results are presented in table 3. ICERs
were sensitive to different assumptions made for the utility
values between strategies, or when the time horizon of the
analysis was extended or shortened. For example, using a
1-year time horizon instead of a 2-year time horizon in-
creased the ICER by 34.0%, whereas using a 4-year time
horizon in fact decreased the ICER by 36.0%. Results re-
mained the same when two other methods for estimating
hospital inpatient costs were used. Use of utility values
from the Spine Patient Outcomes Research Trial (SPORT)
[6], where chronically ill patients with a longer duration
of symptoms than our population of interest were enrolled,
improved the ICER substantially (decrease of ICER by
70.0%). Furthermore, the ICER was increased by 70.0%,
from a societal perspective when PST patients who did
not undergo surgery but continued with PCT were mod-
elled with the same costs and effects as those seen with
the PCT approach, and PCT patients who crossed over to
surgery with the same costs and effects as seen with the
PST approach. Additionally, in the scenario analysis which
assumed no difference in utility scores in the second year
between PST and PST, the ICER was increased to CHF 99
745, from a societal perspective.
PSA results are presented as cost-effectiveness scatterplots
in figure 2 and figure 3. The results fell within the upper
right of the cost-effectiveness plane, indicating that the
PST approach was more costly and more effective. The dis-
tribution indicated substantial uncertainty in the modelled
economic results. In the analysis from the healthcare sys-
tem perspective, the 2.5th and 97.5th percentiles for ICERs
were CHF 65 869 and CHF 275 461 per QALY gained, re-
spectively (fig. 2). From the societal perspective, the 2.5th
and 97.5th percentiles for ICERs ranged from being cost
saving (dominant) to CHF 273 431 per QALY gained, re-
spectively (fig. 3).
Discussion
The cost-effectiveness of PST versus PCT was assessed in
adults with acute or subacute lumbar radicular syndrome
due to intervertebral disc herniation. The ICER for PST
was CHF 113 396 per QALY gained over 2 years, from
the Swiss healthcare system perspective. From the societal
perspective, the ICER of PST was improved to CHF 70
711 per QALY gained. In Switzerland, there is no official
threshold for cost-effectiveness, and in this situation we
have used a willingness to pay (WTP) threshold of CHF100
000 per QALY gained as tentative reference [23, 24]. As-
suming a WTP threshold of CHF100 000 per QALY
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gained, a PST approach, when compared with PCT, may
be cost-effective from a societal perspective. However, it
is less likely to be cost-effective from the Swiss healthcare
system perspective. It should be noted that our cost-effect-
iveness results are valid only for patients with moderate
disease severity, not for patients with severe neurological
symptoms that suggest an operation is imperative, or for
patients with only minor discomfort.
Compared with analyses for other countries, our ICER es-
timates for Switzerland are substantially less favourable for
PST. This is mainly due to differences in methodologic-
al approaches, time horizon of analysis, utility parameters
used and cost differences between strategies. For example,
the Dutch study by van den Hout et al. [5] reported early
surgery to be cost-effective from a societal perspective,
with an ICER for PST of EUR 41 000 per QALY gained. In
this study, the total cost difference between strategies was
substantially lower owing to lower surgery costs and oth-
er related costs. Some US studies showed favourable ICER
results for PST driven by substantially higher QALY differ-
ences than in our study. For example, Malter et al. [7], par-
tially based on the clinical trial by Weber et al. [1], reported
that surgery gained 0.43 QALYs and that, from a payer per-
spective, surgical discectomy was a cost-effective strategy
with an ICER of USD 33 900 per QALY gained during
10 years of follow-up. Even after the first 12 months, the
QALY difference between surgical discectomy and medic-
al management was 0.10, considerably higher than in our
base-case analysis (QALY gained in the first year 0.0450).
However, the underlying utility estimates were generated
indirectly by combination of clinical parameters with pref-
erences elicited from persons with a history of lumbar spine
symptoms. A recent study by Koenig et al. [4], who based
their effectiveness results on the SPORT study and Malter
Table 1: Base-case results (healthcare system and societal perspective) of the decision model comparing primarily surgical treatment with primarily conservative treatment
approach. The results are expressed per person.
Parameters Primarily surgical treatment Primarily conservative
treatment
Difference
QALYs (discounted) 1.554 1.490 0.0634
Costs (discounted)
Cost of surgery, reimbursed by statutory health insurance 5350 2003 3347
Cost of surgery, cantonal contribution 6539 2448 4091
Physiotherapy costs 1164 1325 −160
Drug costsa 252 321 −69
Physician and other healthcare costsb 2297 2309 −11.99
Total healthcare costs 15 604 8406 7198
Costs of lost productivityc 26 192 28 901 −2,709
Total costs from the societal perspective 41 796 37 307 4489
Incremental cost-effectiveness ratio (cost per QALY gained, discounted)
Healthcare system perspective 113 396d
Societal perspective 70 711e
QALY = Quality Adjusted Life Year; ICER = incremental cost effectiveness ratio. Healthcare system perspective for hospital costs – 45.0% of costs covered by the statutory
health insurance and 55.0% by cantonal contributions.
a Drug costs include drugs from the following ACT groups: H02, M01, M02, M03, N01, N02, N05, N06.
b Physician and other healthcare costs include cost of general medicine, physiotherapy, chiropractic, ergotherapy, neurosurgery, neurology, rheumatology, attendance at a
rheumatology or rehabilitation hospital, and therapeutic bath.
c Indirect costs of absence from work due to discal hernia.
d Healthcare system perspective (ICER = 7198 / 0.0634 = 113 396).
e Societal perspective (ICER = 4489 / 0.0634 = 70 711).
(All costs in 2015 CHF).
Table 2: Deterministic sensitivity analysis, comparing primarily surgical treatment (PST) with primarily conservative treatment (PCT).
Incremental cost-effectiveness ratioBase-case model from a healthcare system perspective
113,396
Input parameters Low parameter values High parameter values
Hospital costs 111 186 129 795
Physiotherapy costs for PST over 24 months 111 852 114 941
Physiotherapy costs for PCT over 24 months 115 154 111 638
Cost of medications, including all ATC codes 113 535 113 257
General practice costs for PST 112 025 114 768
General practice costs for PCT 114 905 111 888
Neurosurgery costs for PST 112 944 113 848
Neurosurgery costs for PCT 113 625 113 167
Utility value ranges 87 228 161 995
Crossover from PCT to PST 132 344 92 554
Reoperation at 24 months, PST 106 895 119 898
Reoperation at 24 months, PCT 117 078 109 101
Difference in productivity costs between PST vs. PCT (societal perspective) 186 728 Dominant, cost saving
a Variation of input parameters was based on the information that was presented in the appendices 2 and 3.
(All costs in 2015 CHF)
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et al. [6, 7], and used the same utility estimates as Mal-
ter et al., calculated an ICER of USD 52 416 per QALY
gained. When costs of lost productivity were incorporated
into the results, the ICER was USD 4 186 (societal per-
spective). Koenig et al. classified patients according to ac-
tual treatment received, not primary treatment approach,
which affects comparability. This was also true for an ana-
lysis from a societal perspective based on the SPORT study
by Tosteson et al. [6], which reported a cost per QALY
gained of USD 69 403 for all age groups and USD 34 355
for individuals aged 65 years and older [6]. Some patients
enrolled in the SPORT study were chronically ill, with a
longer duration of symptoms than in our population of in-
terest, and which limits comparability with our study pop-
ulation [6]. An invstigation from a societal perspective by
Hansson et al. [12] was based on patients with at least 28
days of sick leave prior to enrolment into the prospective
cohort study, and is thus also potentially not comparable
with our study population. It showed favourable results for
surgery, as a result of a QALY difference of 0.327 after the
second year.
The present study had several limitations. Firstly, clinical
data indicated that the impact of the initial treatment ap-
proach was limited to 2 years [5, 15]. There was, however,
a lack of reliable information on longer-term utility values
and cost data. We addressed this uncertainty in scenario
analyses. For example, the model was run over 4 years,
with each base-case value kept and extended to 4 years,
except that no costs were attached to the third and fourth
years. The corresponding ICER was CHF 45 178 per
QALY gained form a societal perspective.
Secondly, our estimates of costs were based on health in-
surance claims data that may not be perfectly representat-
ive of the Swiss population, as the Helsana enrolees have
a slightly higher average age. This is a common practice.
However, the selection of patients based solely on the
SwissDRGs I53Z and I56Z is relatively nonspecific, which
might lead to the inclusion of a relevant proportion of pa-
tients not meeting the intended inclusion criteria. To ac-
count for this uncertainty around surgery costs, two other
sources of information were used, namely information on
the costs of SwissDRGs provided by the Swiss Ferderal
Office of Public Health and Swiss statistical data on hospit-
alisations. The results of both were similar with the estim-
ations of health insurance claims data.
Thirdly, over-the-counter costs directly paid by the patients
could not be considered, and indirect costs are theoretically
comprised of more than just lost working hours, such as the
possibility of early retirement, reduced degree of employ-
ment, or reduced paid work of family caregivers. There-
fore, our approximation of the societal perspective is lim-
ited.
Additionally, the insurance claims data did not allow for
the identification of subjects who only received conservat-
ive treatment but did not undergo surgery. We could not
directly distinguish between use of resources and costs re-
lated and unrelated to disc herniation. However, based on
information from the literature and answers received from
clinical experts, efforts were made to achieve a reason-
able approximation of the cost differences between the two
strategies, and to assess the impact of related uncertainty.
Utility values used in the base-case analysis were derived
from only one Dutch study [5]. In a scenario analysis, util-
ity values based on a meta-analysis of data from two clin-
ical trials yielded consistent results. The assumption that
utility values remain the same in year 2 as in year 1 was
potentially in favour of PST. To address this limitation,
we performed additional scenario analyses in which we as-
sumed no difference in utility scores between the PST and
PCT approaches. The corresponding ICER from a societal
perspective was CHF 99 745 per QALY gained.
The surgery rate in the conservative treatment group (pa-
tients who crossed over from conservative treatment to sur-
gery) in the base-case analysis was 37.0%. If the crossov-
Table 3: Scenario analysis for the decision analytical model, comparing primarily conservative treatment (PCT) with primarily surgical treatment (PST).
Parameters Values ICER (Cost per QALY)
Healthcare system perspective
Base-case model from healthcare system perspective 113,396
Time framea 1 year 152,257
Time frameb 4 years 72,451
No difference in utility scores in the second year between PST and PCT Utility scores (PST: 0.84; PCT 0.84) 159,957
Utility values from pooled meta-analysisc PST (0.66; 0.87; 0.849; 0.849):
PCT (0.62; 0.816; 0.839; 0.839)
139,124
Utility value differences between strategies derived from SPORT trial [6] 0.21 34,272
Hospital costs for surgery based on DRG codes (I53Z, I56Z) 9911 98,126
Hospital costs for surgery calculated using data on cost per day in a Swiss acute care
hospital
12,264 122,330
Societal perspective
Base-case model from societal perspective 70,711
Time frameb 4 years 45,178
No difference in utility scores in the second year between PST and PCT Utility scores (PST: 0.84; PCT 0.84) 99,745
Productivity cost data from Koenig et al. only for first 12 months [4] 3,022 85,105
Productivity cost data from Koenig et al. only for 24 months [4]d 6,044 21,811
No cost attached in second year to productivity lost 91,209
a 1-year time frame, each base-case value was kept the same, except time frame.
b 4-year time frame, each base-case value was kept and extended to 4 years, except no costs were attached to 3rd and 4th year.
c Utility values derived from pooled meta-analysis of the studies Österman et al. and van den Hout et al. [5, 15].
d Koenig (2014), cost data about productivity, participants in the PST approach earned over 24 months CHF 6,044 more than PCT approach.
(All costs in 2015 CHF)
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er percentage had been lower, better results might poten-
tially have been achieved, leading to larger differences in
QALYs. If the crossover percentage had been higher than
37%, it might have affected the ICERs in either direction.
The results presented here may reasonably reflect true
ICERs for our target population with acute and subacute
sciatica in Switzerland. However, they are sensitive to as-
sumptions made in the model and potentially affected by
substantial uncertainty in some model input parameters,
specifically utility parameters and estimates of productivity
costs. More research is needed to achieve a firm under-
standing of the long-term health economic implications of
alternative treatment approaches in the population of in-
terest. There is a need for better information on quality of
life beyond 12 months of follow up, and cost data that al-
low use of resources and costs related to disc herniation to
be more precisely distinguished from those unrelated.
Conclusion
A PST approach, when compared with a PCT approach,
may be cost-effective from the societal perspective based
on a willingness to pay threshold of CHF100 000 per
QALY gained. However, it is less likely to be a cost-effect-
ive treatment approach from the perspective of the Swiss
healthcare system. More research is needed to understand
the long-term economic implications of treatment ap-
proaches among this patient group.
Acknowledgment: We would like to thank Prof, Dr. Andreas
Raabe, PD Dr. Stephan Reichenbach, Dr. Gaby Eglseer, Prof.
Dr. Constantin Schizas, Dr. Anna Thoma, and Dr. Stephan Marx
for their expertise and help during the scoping process. The
authors are solely responsible for the content of the manuscript.
This manuscript was based on a report previously published by
the Swiss Medical Board (http://www.medical-board.ch/
fileadmin/docs/public/mb/berichte/
SMB_Assessment_Diskushernien_pub.pdf). Some information
provided in the manuscript differs slightly from the initial report,
owing to updates of cost data to the year 2015 and additional
assumptions made in the model.
Disclosure statement: This study was funded by Swiss
Medical Board, Switzerland.
Correspondence: Dr Zanfina Ademi, Pharm, PhD, MPH,
Institute of Pharmaceutical Medicine (ECPM), University of
Basel, CH-4031 Basel, zanfina.ademi[at]unibas.ch
References
1 Weber H. Lumbar disc herniation. A controlled, prospective study
with ten years of observation. Spine. 1983;8(2):131–40. doi:ht-
tp://dx.doi.org/10.1097/00007632-198303000-00003.
2 Agency for Healthcare Research and Quality. Health-Care-Costs and
Utilization Project. Available at: http://hcupnet.ahrq.gov/HCUPnet.jsp.
3 Medizinische Statistik der Krankenhäuser: Anzahl Fälle und durch-
schnittliche Aufenthaltsdauer nach Altersklasse und Behandlungskode,
excel file. 2012 [cited 2014 July 2014]; Available from: ht-
tp://www.bfs.admin.ch/bfs/portal/de/index/themen/14/04/01/data/01/
05.html.
4 Koenig L, Dall TM, Gu Q, Saavoss J, Schafer MF. How does ac-
counting for worker productivity affect the measured cost-effectiveness
of lumbar discectomy? Clin Orthop Relat Res. 2014;472(4):1069–79.
doi:http://dx.doi.org/10.1007/s11999-013-3440-6.
5 van den Hout WB, Peul WC, Koes BW, Brand R, Kievit J, Thomeer
RT; Leiden-The Hague Spine Intervention Prognostic Study Group.
Prolonged conservative care versus early surgery in patients with sci-
atica from lumbar disc herniation: cost utility analysis alongside a
randomised controlled trial. BMJ. 2008;336(7657):1351–4. doi:ht-
tp://dx.doi.org/10.1136/bmj.39583.709074.BE.
6 Tosteson AN, Skinner JS, Tosteson TD, Lurie JD, Andersson GB, Ber-
ven S, et al. The cost effectiveness of surgical versus nonoperative
treatment for lumbar disc herniation over two years: evidence from
the Spine Patient Outcomes Research Trial (SPORT). Spine.
2008;33(19):2108–15. doi:http://dx.doi.org/10.1097/
BRS.0b013e318182e390.
7 Malter AD, Weinstein J. Cost-effectiveness of lumbar discectomy.
Spine. 1996;21(24, Suppl):69S–74S. doi:http://dx.doi.org/10.1097/
00007632-199612151-00008.
8 Fitzsimmons D, Phillips CJ, Bennett H, Jones M, Williams N, Lewis R,
et al. Cost-effectiveness of different strategies to manage patients with
sciatica. Pain. 2014;155(7):1318–27. doi:http://dx.doi.org/10.1016/
j.pain.2014.04.008.
9 Österman H, Seitsalo S, Karppinen J, Malmivaara A. Effectiveness of
microdiscectomy for lumbar disc herniation: a randomized controlled
trial with 2 years of follow-up. Spine. 2006;31(21):2409–14. doi:ht-
tp://dx.doi.org/10.1097/01.brs.0000239178.08796.52.
10 Peul WC, van Houwelingen HC, van der Hout WB, Brand R, Eekhof
JA, Tans JT, et al. Prolonged conservative treatment or ‘early’ surgery
in sciatica caused by a lumbar disc herniation: rationale and design
of a randomized trial [ISRCT 26872154] [ISRCT 26872154]. BMC
Musculoskelet Disord. 2005;6(1):8. doi:http://dx.doi.org/10.1186/
1471-2474-6-8.
11 Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Eco-
nomic Evaluation. Oxford: Oxford University Press; 2006.
12 Hansson E, Hansson T. The cost-utility of lumbar disc herniation sur-
gery. Eur Spine J. 2007;16(3):329–37. doi:http://dx.doi.org/10.1007/
s00586-006-0131-y.
13 Gesundheitsdirektion des Kantons Zürich. Beurteilung medizinischer
Verfahren. Zollicon: medical board: 2009. p. 14.
14 Peul WC, van den Hout WB, Brand R, Thomeer RT, Koes BW; Leiden-
The Hague Spine Intervention Prognostic Study Group. Prolonged con-
servative care versus early surgery in patients with sciatica caused by
lumbar disc herniation: two year results of a randomised controlled
trial. BMJ. 2008;336(7657):1355–8. doi:http://dx.doi.org/10.1136/
bmj.a143.
15 Österman H, Seitsalo S, Karppinen J, Malmivaara A. Effectiveness of
microdiscectomy for lumbar disc herniation: a randomized controlled
trial with 2 years of follow-up. Spine. 2006;31(21):2409–14. doi:ht-
tp://dx.doi.org/10.1097/01.brs.0000239178.08796.52.
16 OECD consumer price index. Available from: https://stats.oecd.org/in-
dex.aspx?queryid=221#
17 Bundesamt für Statistik. Cost per DRG. 2011 July 2014]; Available
from: http://www.bfs.admin.ch/bfs/portal/de/index/themen/14/01/new/
nip_detail.html?gnpID=2013-210.
18 Erhebungen, Quellen – Krankenhausstatistik. 2014 [cited 2014]; Avail-
able from: http://www.bfs.admin.ch/bfs/portal/de/index/infothek/er-
hebungen__quellen/blank/blank/kh/06.html.
19 WHO. Collaborating Centre for Drug Statistics Methodology,
Guidelines for ATC classification and DDD assignment 2014. 2014,
World Health Organization: Oslo, 2013.
20 Landefeld JS, Seskin EP. The economic value of life: linking theory to
practice. Am J Public Health. 1982;72(6):555–66. doi:http://dx.doi.org/
10.2105/AJPH.72.6.555.
21 Swiss Federal Statistical Office. Work and income. 2012 [cited August
2014; Available from: http://www.bfs.admin.ch/bfs/portal/en/index/
themen/03.html.
22 Wages and income from employment – Indicators. Available from:
http://www.bfs.admin.ch/bfs/portal/en/index/themen/03/04/blank/key/
lohnentwicklung/quartal.html.
Original article Swiss Med Wkly. 2016;146:w14382
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 7 of 14
23 Brändle M, Goodall G, Erny-Albrecht KM, Erdmann E, Valentine WJ.
Cost-effectiveness of pioglitazone in patients with type 2 diabetes and
a history of macrovascular disease in a Swiss setting. Swiss Med Wkly.
2009;139(11-12):173–84.
24 Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG.
Willingness to pay for a quality-adjusted life year: in search of a stand-
ard. Med Decis Making. 2000;20(3):332–42. doi:http://dx.doi.org/
10.1177/0272989X0002000310.
Original article Swiss Med Wkly. 2016;146:w14382
Swiss Medical Weekly · PDF of the online version · www.smw.ch Page 8 of 14
Appendix 1
Rate of crossover and reoperation in both arms – primary surgical treatment and primarily conservative treatment (PST and PCT) –
derived from clinical trials
a) Proportion of crossover in the PST group at 1 year.
b) Proportion of crossover in the PCT group at 1 year.
c) Proportion of reoperations in the PCT group over 24 months of follow up.
d) Proportion of reoperations in the PST over 24 months of follow up.
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Appendix 2
Input parameters for the decision model comparing primarily surgical treatment (PST) with primarily conservative treatment (PCT).
Base-case
value
Range of variation in
sensitivity analyses
Basis of variation: distribution
type in PSA
Reference
Parameters
Percentage not operated, PST 2% 1–3% γ distribution with mean and SE Peul et al. and Weber et
al. [1, 2]
Percentage that undergo surgery, PCT 37% 27–48% γ distribution with mean and SE Peul et al., Österman et
al. and Weber et al.
[1–3]
Reoperation in 24 months, PST 7.0% 3–11% γ distribution with mean and SE Peul et al. and
Österman et al. [1, 3]
Reoperation in 24 months, PCT 6.0% 0–13% γ distribution with mean and SE Peul et al. and
Österman et al. [1, 3]
Parameters regarding probability of drug use
Oral steroids, 12 months, PST 21.25% 15–28% ±30.0 uniform distribution Expert opinion
Oral steroids, 12 months, PCT 16.25% 11–21% ±30.0 uniform distribution Expert opinion
Muscle relaxants and cox-inhibitors, 12 months, PST 57.78% 40–75% ±30.0 uniform distribution Expert opinion
Muscle relaxants and COX-inhibitors, 12 months, PCT 62.22% 44–81% ±30.0 uniform distribution Expert opinion
Narcotics and Antidepressants, 12 months, PST 28.13% 20–37% ±30.0 uniform distribution Expert opinion
Narcotics and Antidepressants, 12 months, PCT 28.33% 20–37% ±30.0 uniform distribution Expert opinion
Muscle relaxants and cox-inhibitors, 24 months, PST 13% 9–17% ±30.0 uniform distribution Expert opinion
Muscle relaxants and COX-inhibitors, 24 months, PCT
approach
23% 16–30% ±30.0 uniform distribution Expert opinion
Narcotics and Antidepressants, 24 months, PST 8% 5–10% ±30.0 uniform distribution Expert opinion
Narcotics and Antidepressants, 24 months, PCT 20% 14–26% ±30.0 uniform distribution Expert opinion
Utility values, PST
1st quartile 0.63 0.52–0.74 β distribution van den Hout et al. [4]
2nd quartile 0.81 0.75–0.87 β distribution van den Hout et al. [4]
3rd quartile 0.83 0.78–0.88 β distribution van den Hout et al. [4]
4th quartile 0.84 0.79–0.89 β distribution van den Hout et al. [4]
Second year 0.84 0.79–0.89 β distribution van den Hout et al. [4]
Utility values, PCT
1st quartile 0.57 0.44–0.69 β distribution van den Hout et al. [4]
2nd quartile 0.74 0.66–0.81 β distribution van den Hout et al. [4]
3rd quartile 0.8 0.74–0.86 β distribution van den Hout et al. [4]
4th quartile 0.82 0.76–0.87 β distribution van den Hout et al. [4]
Second year 0.82 0.76–0.87 β distribution van den Hout et al. [4]
COX = cyclooxygenase; PSA = probabilistic sensitivity analysis; SE = standard error
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Appendix 3
Cost parameters for the decision model, comparing primarily surgical treatment (PST) with primarily conservative treatment (PCT)
approach.
Base-case
value
Range of variation in
sensitivity analyses
Basis of variation: distribution
type in PSA
Parameters – Unit costs (CHF)
Hospital costs (DRG codes: I53Z, I56Z), derived from Helsana data1 5128 (5031–5845) γ distribution
Additional hospital costs covered by cantonal contribution2 6267 (6149–7144) γ distribution
Average inpatient cost per day using Swiss statistical hospital data for I53Z, I56Z [5, 6] 5518 *Alternative data for hospital
costs
Average inpatient cost per day using Swiss statistical hospital data for I53Z, I56Z 6745 *Alternative data for hospital
costs
DRG codes: I53Z, I56Z, derived from FSO [7, 8] 4460 *Alternative data for hospital
costs
DRG codes: I53Z, I56Z, derived from FSO covered by cantonal contribution 5451 *Alternative data for hospital
costs
Data for the following costs derived from Helsana
Physiotherapy cost, 12 months, PST approach 733 (690–778) γ distribution
Physiotherapy cost, 24 months, PST approach 465 (407–524) γ distribution
Physiotherapy cost, 12 months, PCT approach3 835 (785–885) γ distribution
Physiotherapy cost, 24 months, PCT approach 530 (463–597) γ distribution
Cost of medication, ATC code H02, 12 months 52 (48–56) γ distribution
Cost of medication, ATC codes M01, M02, and M03, 12 months 129 (121–138) γ distribution
Cost of medication, ATC codes N01, N02, N05, and N06, 12 months 419 (381–457) γ distribution
Cost of medication, ATC code H02 63 (54–73) γ distribution
Cost of medication, ATC codes M01, M02, and M03 134 (116–150) γ distribution
Cost of medication, ATC codes N01, N02, N05, and N06 455 (394–516) γ distribution
Chiropractic costs, 12 months 18 (13–22) γ distribution
Chiropractic costs, 24 months 24 (14–34) γ distribution
Ergotherapy, 12 months 18 (5–31) γ distribution
Ergotherapy, 24 months 19 (6–34) γ distribution
General practice, 12 months, PST approach 721 (685–758) γ distribution
General practice, 12 months, PCT approach4 793 (753–834) γ distribution
General practice, 24 months, PST approach 717 (662–771) γ distribution
General practice, 24 months, PCT approach 789 (729–849) γ distribution
Neurosurgery, 12 months PST approach 105 (92–119) γ distribution
Neurosurgery, 24 months PST approach 45 (29–61) γ distribution
Neurology, 12 months, PST approach 52 (40–64) γ distribution
Neurology, 24 months, PST approach 62 (44–78) γ distribution
Neurosurgery, 12 months, PCT approach5 54 (46-60) γ distribution
Neurosurgery, 24 months, PCT approach 22 (14–32) γ distribution
Neurology, 12 months, PCT approach5 26 (20–32) γ distribution
Neurology, 24 months, PCT approach 31 (23–40) γ distribution
Rheumatology, 12 months 78 (64–92) γ distribution
Rheumatology, 24 months 72 (54–90) γ distribution
Rheuma- und Rehabilitation clinic, 12 months6 426 (340–512) γ distribution
Therapeutic baths (Heilbäder), 12 months 5 (1–8) γ distribution
Therapeutic baths (Heilbäder), 24 months 4 (−3–10) γ distribution
Difference in productivity cost PST vs PCT, 12 months 1408 (−2419–5200) γ distribution
Difference in productivity cost PST vs PCT, 24 months 1408 (−2419–5200) γ distribution
ATC = anatomical therapeutic class; DRG = diagnosis-related group; FSO = Swiss Federal Statistical Office; PSA = probabilistic sensitivity analysis
Costs were derived from Swiss health insurance claims data provided by Helsana, and updated to values for the year 2015.
1,2 Hospital costs were assumed to be covered by the statutory health insurance (45%) and by cantonal contribution (55%). The base-case value reflects the mean value of
the input parameter. Range of variation for cost values reflected the 95% CI derived from Helsana health insurance claims data.
3 In accordance with van den Hout et al. [4], patients in the PCT approach used 13.8% more physiotherapy services in the first year than patients in the PST approach. The
same proportion was assumed for the second year.
4 The assumption was made that the PCT approach would involve 10% more general practice visits than the PST approach in the first and second year.
5 The assumption was made that PCT approach would involve 50% less neurosergery and neurology based on van den Hout et al. [4].
6 Rheuma- und Rehabilitation clinic, information was available only for the first 12 months from statutory health insurance data (i.e. Helsana).
* This information was used in the scenario analyses. The average cost for DRG I53Z and I56Z was CHF 12 264.I53Z (Andere Eingriffe an der Wirbelsäule ohne äusserst
schwere CC, mit komplexem Eingriff oder Halotraktion) and I56Z (Andere Eingriffe an der Wirbelsäule ohne äusserst schwere CC, ohne komplexen Eingriff oder
Implantation eines interspinösen Spreizers).
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Appendix 4
Utility values from pooled Meta-Analyses from van den Hout and Österman study.
a) Mean utility values for 3 months comparing PST versus PCT.
b) Mean utility values for 6 months comparing PST versus PCT.
c) Mean utility values for 12 months comparing PST versus PCT.
Mean values represent pooled utility values at 3, 6 and 12 months of follow up, based on random effects meta-analyses of the values reported
by Österman et al. [3] and van den Hout et al. [4]. These values were only use in a scenario analysis.
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Figures (large format)
Figure 1
Decision analysis tree comparing primarily conservative treatment (PCT) with primarily surgical treatment (PST) approach.
Figure 2
Scatter plot of incremental costs per person and incremental effectiveness derived from 10 000 iterations of the Monte Carlo simulation.
Incremental effectiveness is expressed as quality adjusted life years (QALYs) gained and incremental costs are in CHF, from the healthcare
system perspective.
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Figure 3
Scatter plot of incremental costs per person and incremental effectiveness derived from 10 000 iterations of the Monte Carlo simulation.
Incremental effectiveness is expressed as quality adjusted life years (QALYs) gained and incremental costs are in CHF, from the societal
perspective.
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